Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Brachial plexus neuromuscular ultrasound in neuralgic amyotrophy
Feaster, Brandon W, Meiling, James B. , Meiling, James B

BMJ Case Reports | April 11, 2025 | Volume: 18 | Issue: 4 | Pages: e265588

10.1136/bcr-2025-265588 | PMID 40216416 Get It

Neuroimmunology and Sleep
Dredla, Brynn K., Braley, Tiffany J.

Seminars in Neurology | April 10, 2025 | Volume: 45 | Issue: 03 | Pages: 420-430

10.1055/a-2559-7565 | PMID 40209761 Get It

AbstractThe immune system and sleep are inextricably linked in both health and pathological conditions. Tightly regulated neuroimmune processes are critical for the physiological maintenance of healthy sleep. Reciprocally, sleep disturbances can detrimentally affect immune homeostasis and predispose to increased risk of autoimmune conditions, which themselves are bidirectionally associated with a higher risk of sleep disturbances. Autoimmune diseases of the central nervous system (CNS), particularly conditions that affect neuroanatomical regions involved in sleep homeostasis and nocturnal respiration, are associated with an increased risk sleep disorders that may impact diagnosis, clinical course, and management. This review summarizes the bidirectional relationship between sleep and immunity and highlights several exemplar autoimmune conditions of the CNS that include sleep disorders as a consequence or diagnostic feature of the disorder.
Anatomical Considerations for Biliary Interventions: Navigating Challenging Cases
Wallace, Alex , Özen, Merve , Patel, Indravadan , Crawford, Daniel , Wallace, Alex

Seminars in Interventional Radiology | April 10, 2025 | Volume: 42 | Issue: 02 | Pages: 166-175

10.1055/s-0045-1806723 | PMID 40376222 Get It

AbstractA thorough understanding of normal biliary anatomy, common variants, and surgically altered anatomy is essential for the success of biliary interventions. Variations in biliary anatomy are seen in up to 40% of patients and frequently influence procedural planning and outcomes. This review highlights classical biliary anatomy, its common variations, and the challenges posed by surgical modifications, such as those encountered after cholecystectomy, liver resection, or biliary reconstructions. Case-based examples are used to explore the implications of these variations and modifications on interventional approaches, including the management of bile leaks, strictures, and complex obstructions. Strategies incorporating advanced imaging and procedural techniques, such as rendezvous interventions, are discussed to address complications and optimize outcomes. This article provides a practical framework for interventional radiologists to navigate challenging biliary cases with confidence and precision.
The Spectrum of Mitral Regurgitation in Lung Transplant Recipients: A Systematic Review
Bcharah, George , Jenkins, Jan , Zeineddine, Rawan M. , Saleeb, Andrew G. , Bcharah, Estefana, Shawwaf, Kenan A. , Hardaway, Brian , Santos, Pedro Reck dos , D’Cunha, Jonathan, Omar, Ashraf, Jenkins, J Asher, Hardaway, Brian W, Reck Dos Santos, Pedro, D'Cunha, Jonathan, Farina, Juan M.

Transplantation | April 10, 2025 | Volume: 109 | Issue: 9 | Pages: e455-e468

10.1097/tp.0000000000005359 | PMID 40200397 Get It

Mitral regurgitation (MR) in lung transplant (LTx) recipients is a rare but complex cardiopulmonary phenomenon. The overlap between symptoms of MR and post-LTx complications, such as primary graft dysfunction, complicates its diagnosis and management. This systematic review aims to characterize the incidence, pathophysiology, presentation, and management of MR in LTx patients. We conducted a literature search in PubMed, Web of Science, Scopus, and Embase. The search yielded 133 studies, of which 11 were included. Data regarding MR development, clinical presentation, echocardiographic findings, and management strategies were extracted and analyzed. Perioperative MR, occurring during or immediately post-LTx, was frequently attributed to the systolic anterior motion of the mitral valve (MV) occurring in the setting of hypovolemia and/or inotrope usage. Later postoperative MR, on the other hand, was associated with reverse ventricular remodeling and mitral annular dilation, although some variability in the literature was present. Preexisting MR or ventricular dysfunction, elongated MV leaflets, and bilateral LTx procedure appeared to be risk factors for MR development. Management was dependent on the timing of MR and its pathophysiology, where systolic anterior motion–related MR was treated with medical therapy, whereas postoperative MR often required MV interventions. In conclusion, the diagnosis of MR in LTx patients is complicated by its symptomatic overlap with other post-LTx complications. Echocardiographic monitoring in patients with preexisting MR, regardless of severity, is essential for early identification and management. Further research is needed to better understand the underlying mechanisms and refine management strategies for MR in this population.
Dimethyl fumarate attenuates bile acid retention and liver fibrosis in a mouse model of cholestasis
Laštůvková, Hana , Dohnálková, Ester , Manna, D., Pejchal, Jaroslav , Hirsova, Petra , Nachtigal, Petr , Bajnokova, Maria , Štefela, Alžběta , Kamaraj, Rajamanikkam , Jandová, Lenka , Uher, Martin , Manna, Dina Faeq , Pejchal, Jaroslav , Hirsova, Petra , Bajnokova, Maria , Smutna, Lucie , Stefela, Alzbeta , Kamaraj, Rajamanikkam , Jandova, Lenka , Pavek, Petr , Micuda, Stanislav , Hroch, Milos , Cermanová, Jolana , Mokrý, Jaroslav , Pávková, Ivona , Mičuda, Stanislav

American Journal of Physiology-Gastrointestinal and Liver Physiology | April 10, 2025 | Volume: 328 | Issue: 5 | Pages: G558-G577

10.1152/ajpgi.00262.2024 | PMID 40210415 Get It

Chronic cholestatic cholangiopathies present a therapeutic challenge due to their complex pathophysiology, where the accumulation of bile acids plays a crucial role. In this study, we found that dimethyl fumarate attenuated cholestatic liver damage in a murine model through its significant anti-inflammatory and antifibrotic activity supported by reduced bile acid accumulation in the plasma and liver via their increased fecal excretion.
Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2 -Amplified Advanced Biliary Tract Cancer
Inoue, Kanae , Nakamura, Yoshiaki , Caughey, Bennett Adam , Zheng-Lin, Binbin , Ueno, Makoto , Furukawa, Masayuki , Itoh, Shinji , Umemoto, Kumiko , Sudo, Kentaro, Kajiwara, Takeshi , Fujisawa, Takao , Morizane, Chigusa , Caughey, Bennett , Kawamoto, Yasuyuki , Itoh, Shinji , Umemoto, Kumiko , Satoh, Taroh , Mizuno, Nobumasa , Kajiwara, Takeshi , Fujisawa, Takao , Bando, Hideaki , Yoshino, Takayuki , Strickler, John H , Morizane, Chigusa , Bekaii-Saab, Tanios S , Ikeda, Masafumi , Nakamura, Yoshiaki , Furukawa, Masayuki , Mizuno, Nobumasa , Bando, Hideaki , Yoshino, Takayuki , Strickler, John H. , Bekaii‐Saab, Tanios , Ikeda, Masafumi

JCO Precision Oncology | April 10, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-24-00718 | PMID 40209139 Get It

PURPOSE This study aimed to investigate the clinicomolecular profiles and the efficacy of human epidermal growth factor receptor 2 (HER2)-targeted therapy in HER2 -amplified biliary tract cancer (BTC). METHODS This study was an international collaboration that used combined data from the prospective SCRUM-Japan GOZILA and MONSTAR-SCREEN in Japan and retrospective reviews in the United States; patients with advanced BTC who had received systemic therapy were included. The clinicomolecular profiles were evaluated in an exploratory cohort, whereas the efficacy of HER2-targeted therapy was assessed in a biomarker-selected cohort. RESULTS Of the 439 patients in the exploratory cohort, 43 (10%) had HER2 amplification. The frequencies of coalterations were higher in patients with HER2 amplification versus patients without HER2 amplification including HER2 mutations (26% v 5%, P < .001), TP53 mutations (84% v 61%, P = .003), and BRAF amplification (9% v 2%, P = .030). There were no KRAS mutations identified in patients with HER2- amplified BTC. No significant difference in overall survival (OS) was observed between patients with and without HER2 amplification (median, 17.7 v 16.9 months; hazard ratio [HR], 0.95 [95% CI, 0.65 to 1.40]). Of the 60 patients with HER2 -amplified BTC in the biomarker-selected cohort (43 from Japan and 17 from the United States), the OS was significantly longer in 29 patients who received HER2-targeted therapy than in those who did not receive HER2-targeted therapy (median, 24.3 v 12.1 months; HR, 0.39 [95% CI, 0.23 to 0.82]). Multivariate analysis identified HER2-targeted therapy as an independent prognostic factor for OS (HR, 0.29 [95% CI, 0.14 to 0.58]; P < .001). CONCLUSION HER2 amplification was found in 10% of advanced BTC and was not identified as an independent prognostic factor for OS. Patients with HER2 -amplified BTC derive significant benefit from HER2-targeted therapy.
The road ahead for chimeric antigen receptor T cells
Stewart, Carli M. , Kenderian, Saad S. , Stewart, Carli , Siegler, Elizabeth L.

The Journal of Immunology | April 10, 2025 | Volume: 214 | Issue: 7 | Pages: 1457-1467

10.1093/jimmun/vkaf047 | PMID 40209174 Get It

Abstract Chimeric antigen receptor T (CART) cell therapy is an innovative form of immunotherapy that has shown remarkable and long-term responses in patients with B-cell malignancies. Over the years, the field has made significant progress in our understanding of the successes and challenges associated with CART cell therapy. In this review, we provide an overview of the current state of CART cell therapy in the clinic. We detail current challenges including patient access, CART-associated toxicity, tumor heterogeneity, CART cell trafficking, the tumor microenvironment, and different CART cell fates. With each challenge, we review lessons learned, potential solutions and outline areas for future development. Finally, we discuss how the field of engineered cell therapy is moving into the treatment of solid tumors and other diseases beyond cancer.
Patient Interest Is Not Enough: Additional Challenges for DBS in MCI
Tripp, Ellery R. , Ellertson, Marka F. , Lapid, Maria I. , Worrell, Gregory A. , Louis, Erik K. St. , Ellertson, Marka , St Louis, E K , Sharp, Richard R , Lapid, Maria I. , Worrell, Gregory A , Sharp, Richard R.

AJOB Neuroscience | April 10, 2025 | Volume: 16 | Issue: 2 | Pages: 88-90

10.1080/21507740.2025.2474227 | PMID 40208679 Get It

ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia
Flinn, Ian W. , Hill, Brian T. , Maris, Michael B., Ghia, Paolo , Byrne, Michael , Bartlett, Nancy L. , Pagel, John M., Zheng, Yan , Kanska, Justyna, Zhang, Wangshu , Granados, Enrique , Pinilla‐Ibarz, Javier , Kenderian, Saad S. , Flinn, Ian W , Ghia, Paolo , Bartlett, Nancy L , Granados, Enrique , Davids, Matthew S.

Blood | April 10, 2025 | Volume: 146 | Issue: 8 | Pages: 938-943

10.1182/blood.2024027460 | PMID 40209059 Get It

Abstract ZUMA-8 evaluated the safety of brexucabtagene autoleucel (brexu-cel), a CD19-directed autologous chimeric antigen receptor (CAR) T-cell immunotherapy, for patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Patients with ≥2 prior lines of therapy (including a Bruton tyrosine kinase inhibitor) underwent leukapheresis, optional bridging therapy, and conditioning chemotherapy (fludarabine/cyclophosphamide) before infusion of 1 × 106 (cohort 1) or 2 × 106 (cohort 2) anti-CD19 CAR T cells per kg. Patients in cohort 3 (low tumor burden), and cohort 4A (postibrutinib) received 1 × 106 cells per kg. Fifteen patients, median age of 63 years (range, 52-79), were treated in cohorts 1 (n = 6), 2 (n = 3), 3 (n = 3), and 4A (n = 3). Median follow-up was 24.3 months. One dose-limiting toxicity was observed in cohort 3 (grade 4 cytokine release syndrome). Grade ≥3 neurologic events occurred in 3 patients (20%). Seven of 15 patients responded (overall response rate, 47%; complete response [CR], 7%), including all 3 patients in cohort 3 (1 with CR). CAR T-cell expansion occurred in 4 patients (27%), with an apparent weak inverse correlation with absolute lymphocyte count before apheresis. Brexu-cel had no new safety signals in R/R CLL. CAR T-cell expansion and responses occurred in patients with low tumor burden. This trial was registered at www.clinicaltrials.gov as #NCT03624036.
Significant Hyperglycemia in Hospitalized Total Pancreatectomy Patients: Results of a Pilot Prospective Continuous Glucose Monitoring Study
Rizvi, Shafaq , Banerjee, Ayan , Kaur, Ravinder Jeet , Gupta, Sandeep , Kurek, Corey, Desjardins, Donna, Kendrick, Michael L., Truty, Mark J. , Kudva, Yogish C. , Rizvi, Shafaq Raza , Bannerjee, Ayan , Kaur, Ravinder J, Kendrick, Michael L.

Diabetes Technology & Therapeutics | April 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1089/dia.2024.0583 | PMID 40208838 Get It